WHO Unveils Tool to Accelerate Action against Antimicrobial Resistance

By Carlos Onyango
The World Health Organization (WHO) today launched a global campaign urging governments to adopt a tool – Access, Watch and Reserve – (AWaRe) to reduce the spread of antimicrobial resistance, adverse events, and costs.
As an effort to improve medical advancements, WHO Essentials Medicines List (EML), developed the AWaRe tool to contain rising resistance and make antibiotic use safer and more effective.
It classifies antibiotics into three groups – Access, Watch, and Reserve – and specifies which antibiotics to use for the most common and serious infections, which ones should be available at all times in the healthcare system, and those that must be used sparingly or preserved and used only as a last resort.
The ACCESS antibiotics are first- and second-choice options for common infections: they should be available in all countries and all facilities.
WHO recommends that antibiotics in the ACCESS group be available at all times as treatments for a wide range of common infections. Examples include amoxicillin, a widely-used antibiotic to treat infections such as pneumonia.
The WATCH group includes antibiotic classes that should be prescribed only for specific indications since they are at higher risk of bacterial resistance. Some ACCESS antibiotics, such as ceftriaxone or azithromycin, are also part of the WATCH group.
And the RESERVE group is made up of last-resort options, such as Colistin or IV Fosfomycin.
Antibiotics belonging to the WATCH and RESERVE groups should be particularly targeted by antibiotic stewardship programs at national and international levels.
The campaign aims at improving the proportion of global consumption of antibiotics in the Access group to at least 60%, and to reduce the use of the antibiotics most at risk of resistance from the Watch and Reserve groups. Using Access antibiotics lowers the risk of resistance because they are ‘narrow-spectrum’ antibiotics (that target a specific microorganism rather than several). They are also less costly because they are available in generic formulations.
“Antimicrobial resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
“All countries must strike a balance between ensuring access to life-saving antibiotics and slowing drug resistance by reserving the use of some antibiotics for the hardest-to-treat infections. I urge countries to adopt AWaRe, which is a valuable and practical tool for doing just that.”
Dr Hanan Balkhy, WHO Assistant Director-General for Antimicrobial Resistance, recommends that in order to tackle antimicrobial resistance, a careful balance between access and preservation is required. She further adds that the aware tool can guide policy to ensure patients keep being treated, while also limiting the use of antibiotics most at risk of resistance.
In the absence of new significant investments into the development of new antibiotics, improving the use of antibiotics is one of the key actions needed to curb further emergence and spread of antimicrobial resistance. By classifying antibiotics into three distinct groups, and advising on when to use them, AWaRe makes it easier for policy-makers, prescribers and health workers to select the right antibiotic at the right time, and to protect endangered antibiotics.
“Antimicrobial resistance is an invisible pandemic,” said Dr Mariângela Simão, Assistant-Director General for Access to Medicines. “We are already starting to see signs of a post-antibiotic era, with the emergence of infections that are untreatable by all classes of antibiotics. We must safeguard these precious last-line antibiotics to ensure we can still treat and prevent serious infections.”
WHO has been leading multiple initiatives to address antimicrobial resistance:
World Antibiotic Awareness Week
Held every November since 2015 with the theme “Antibiotics: Handle with care”, the global, multi-year campaign has an increasing volume of activities during the week of the campaign.
The Global Antimicrobial Resistance Surveillance System (GLASS)
The WHO-supported system supports a standardized approach to the collection, analysis and sharing of data related to antimicrobial resistance at a global level to inform decision-making, drive local, national and regional action.
Global Antibiotic Research and Development Partnership (GARDP)
A joint initiative of WHO and Drugs for Neglected Diseases initiative (DNDi), GARDP encourages research and development through public-private partnerships. By 2023, the partnership aims to develop and deliver up to four new treatments, through the improvement of existing antibiotics and acceleration of the entry of new antibiotic drugs.
Interagency Coordination Group on Antimicrobial Resistance (IACG)
The United Nations Secretary-General has established IACG to improve coordination between international organizations and to ensure effective global action against this threat to health security. The IACG is co-chaired by the UN Deputy Secretary-General and the Director General of WHO and comprises high-level representatives of relevant UN agencies, other international organizations, and individual experts across different sectors.
The AWaRe campaign – ‘AdoptAWaRe, Handle antibiotics with care’ – will be officially launched on 19 June by the Ministers of Health of The Netherlands and Indonesia and WHO Assistant-Director General Hanan Balkhy, at the second ministerial conference on AMR in Noordwijk, The Netherlands. The campaign web site AdoptAWaRe.org provides advocacy and communication materials and resources for policymakers.
READ ALSO: Deadly Ebola Virus Confirmed in Uganda – WHO
About Soko Directory Team
Soko Directory is a Financial and Markets digital portal that tracks brands, listed firms on the NSE, SMEs and trend setters in the markets eco-system.Find us on Facebook: facebook.com/SokoDirectory and on Twitter: twitter.com/SokoDirectory
- January 2026 (220)
- February 2026 (246)
- March 2026 (286)
- April 2026 (191)
- January 2025 (119)
- February 2025 (191)
- March 2025 (212)
- April 2025 (193)
- May 2025 (161)
- June 2025 (157)
- July 2025 (227)
- August 2025 (211)
- September 2025 (270)
- October 2025 (297)
- November 2025 (230)
- December 2025 (219)
- January 2024 (238)
- February 2024 (227)
- March 2024 (190)
- April 2024 (133)
- May 2024 (157)
- June 2024 (145)
- July 2024 (136)
- August 2024 (154)
- September 2024 (212)
- October 2024 (255)
- November 2024 (196)
- December 2024 (143)
- January 2023 (182)
- February 2023 (203)
- March 2023 (322)
- April 2023 (297)
- May 2023 (267)
- June 2023 (214)
- July 2023 (212)
- August 2023 (257)
- September 2023 (237)
- October 2023 (264)
- November 2023 (286)
- December 2023 (177)
- January 2022 (293)
- February 2022 (329)
- March 2022 (358)
- April 2022 (292)
- May 2022 (271)
- June 2022 (232)
- July 2022 (278)
- August 2022 (253)
- September 2022 (246)
- October 2022 (196)
- November 2022 (232)
- December 2022 (167)
- January 2021 (182)
- February 2021 (227)
- March 2021 (325)
- April 2021 (259)
- May 2021 (285)
- June 2021 (272)
- July 2021 (277)
- August 2021 (232)
- September 2021 (271)
- October 2021 (304)
- November 2021 (364)
- December 2021 (249)
- January 2020 (272)
- February 2020 (310)
- March 2020 (390)
- April 2020 (321)
- May 2020 (335)
- June 2020 (327)
- July 2020 (333)
- August 2020 (276)
- September 2020 (214)
- October 2020 (233)
- November 2020 (242)
- December 2020 (187)
- January 2019 (251)
- February 2019 (215)
- March 2019 (283)
- April 2019 (254)
- May 2019 (269)
- June 2019 (249)
- July 2019 (335)
- August 2019 (293)
- September 2019 (306)
- October 2019 (313)
- November 2019 (362)
- December 2019 (318)
- January 2018 (291)
- February 2018 (213)
- March 2018 (275)
- April 2018 (223)
- May 2018 (235)
- June 2018 (176)
- July 2018 (256)
- August 2018 (247)
- September 2018 (255)
- October 2018 (282)
- November 2018 (282)
- December 2018 (184)
- January 2017 (183)
- February 2017 (194)
- March 2017 (207)
- April 2017 (104)
- May 2017 (169)
- June 2017 (205)
- July 2017 (189)
- August 2017 (195)
- September 2017 (186)
- October 2017 (235)
- November 2017 (253)
- December 2017 (266)
- January 2016 (164)
- February 2016 (165)
- March 2016 (189)
- April 2016 (143)
- May 2016 (245)
- June 2016 (182)
- July 2016 (271)
- August 2016 (247)
- September 2016 (233)
- October 2016 (191)
- November 2016 (243)
- December 2016 (153)
- January 2015 (1)
- February 2015 (4)
- March 2015 (164)
- April 2015 (107)
- May 2015 (116)
- June 2015 (119)
- July 2015 (145)
- August 2015 (157)
- September 2015 (186)
- October 2015 (169)
- November 2015 (173)
- December 2015 (205)
- March 2014 (2)
- March 2013 (10)
- June 2013 (1)
- March 2012 (7)
- April 2012 (15)
- May 2012 (1)
- July 2012 (1)
- August 2012 (4)
- October 2012 (2)
- November 2012 (2)
- December 2012 (1)
